Loading...
Cassava Sciences, Inc. Warrant
SAVAW•NASDAQ
HealthcareBiotechnology
$0.03
$0.00(0.00%)
Cassava Sciences, Inc. Warrant (SAVAW) Stock Overview
Explore Cassava Sciences, Inc. Warrant’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for SAVAWStats details for SAVAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SAVAWAnalyst Recommendations details for SAVAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
CEO
Mr. Richard Jon Barry
Employees
30
Headquarters
6801 N. Capital of Texas Hwy, Bldg 1, Austin, TX
Founded
2024